Lyso-Thermosensitive Liposomal Doxorubicin + ThermoDox
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colon Cancer Liver Metastasis
Conditions
Colon Cancer Liver Metastasis
Trial Timeline
Sep 1, 2011 → Jun 1, 2013
NCT ID
NCT01464593About Lyso-Thermosensitive Liposomal Doxorubicin + ThermoDox
Lyso-Thermosensitive Liposomal Doxorubicin + ThermoDox is a phase 2 stage product being developed by IMUNON for Colon Cancer Liver Metastasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01464593. Target conditions include Colon Cancer Liver Metastasis.
What happened to similar drugs?
4 of 14 similar drugs in Colon Cancer Liver Metastasis were approved
Approved (4) Terminated (5) Active (6)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01464593 | Phase 2 | Terminated |
Competing Products
20 competing products in Colon Cancer Liver Metastasis